Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study

This study is specifically for adults aged 18 to 75 who have moderate to severe asthma and have already completed a previous study involving amlitelimab. You'll need to be on specific asthma medications consistently, such as certain doses of inhaled steroid treatments along with other regular asthma controllers like LABA, LTRA, LAMA, or methylxanthines. You might also be taking oral steroids, up to a certain limit.

There are also important health considerations. You won't be able to join if you have another long-term lung condition apart from asthma, or if your health has significantly changed since the previous study. Current smoking or vaping, or issues with substance abuse, would also prevent you from participating. Your doctor will carefully review your overall health to make sure joining the study is safe for you.

For women, you cannot be pregnant or breastfeeding, and must not plan to become pregnant. Both men and women will need to use effective contraception if there's any chance of becoming pregnant during the study. If you have any allergies that the study doctor believes might be a risk, you would also not be able to take part.

If you decide to participate, the study will last for up to 156 weeks (about three years), with the treatment itself lasting up to 144 weeks. During this time, you will have a total of 18 visits to the clinic. For the first 24 weeks, you will either receive amlitelimab or a placebo. After this initial period, all participants will receive amlitelimab openly. Throughout the study, the research team will regularly check your asthma symptoms, overall health, and any side effects. This will involve various assessments and tests to monitor the medication's effects and ensure your safety.